1. Attainment of accaha recommended LDL C lowering with statin and ezetimibe statin therapies. (September 2016) Authors: Toth, P.; Bays, H.; Farnier, M.; Jensen, E.; Tomassini, J.; Polis, A.; Foody, J.; Tershakovec, A. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ezetimibe does not increase fasting glucose levels more than statins alone in non-diabetic, hypercholesterolemic patients. Issue 1 (July 2015) Authors: Toth, P.P.; Catapano, A.; Farnier, M.; Foody, J.; Tomassini, J.E.; Jensen, E.; Polis, A.B.; Musliner, T.; Tershakovec, A.M. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ezetimibe does not increase fasting glucose levels more than statins alone in non-diabetic, hypercholesterolemic patients. Issue 1 (July 2015) Authors: Toth, P.P.; Catapano, A.; Farnier, M.; Foody, J.; Tomassini, J.E.; Jensen, E.; Polis, A.B.; Musliner, T.; Tershakovec, A.M. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0503 Major Cardiovascular Events in Patients with Recurrent Gout, Cardiovascular and Chronic Kidney Disease, Initiating on Allopurinol or Febuxostat. (15th July 2016) Authors: Foody, J.; Turpin, R.; Tidwell, B.A.; Eisenberg Lawrence, D.F.; Schulman, K.L. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 374 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Who might benefit from PCSK9 inhibitor treatment? An analysis from the lipid treatment assessment project-2 (LTAP-2). Issue 1 (July 2015) Authors: Waters, D.; Santos, R.; Abreu, P.; Tarasenko, L.; DeMicco, D.; Foody, J. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Who might benefit from PCSK9 inhibitor treatment? An analysis from the lipid treatment assessment project-2 (LTAP-2). Issue 1 (July 2015) Authors: Waters, D.; Santos, R.; Abreu, P.; Tarasenko, L.; DeMicco, D.; Foody, J. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗